So far this season, influenza A(H3N2) viruses have predominated, but other influenza viruses are also circulating.
As an expert in public health law, I can state two things with confidence. First, the U.S. has made enormous strides in preparing for and treating the flu. And second, we still are not nearly as prepared as we need to be for the next pandemic.
No increased risk of incident epilepsy was seen among children who received influenza vaccination during the 2009-2010 influenza season in Norway.
The study had to be cut short when 2 of 4 subjects developed serious toxicities following the third isoniazid-rifapentine dose.
Biktarvy combines bictegravir, an integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), two nucleoside reverse transcriptase inhibitors (NRTIs).
Symfi Lo combines efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), and lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors.
The treatment was developed under the FDA's 'Animal Rule'; where efficacy is determined in animal studies and human studies determine safety and appropriate dosing. The FDA have stated a target action date for TPOXX of August 8, 2018.
Around 1,200 security workers at the winter Olympics in PyeongChang are being kept in their rooms due to a norovirus outbreak that has already sickened 41 people.
Incidences of measles, mumps and pertussis have increased in the U.S. for the first time in a century (WHO, 2017). To identify the 'attitude roots' of vaccine rejection, a survey was issued online and completed by 5,323 usable participants in 24 different countries.
Changes in the 2018 adult immunization schedule from the previous year's schedule include new ACIP recommendations for the use of recombinant zoster vaccine (RZV) for adults aged 50 years or older and the use of an additional dose of measles, mumps, and rubella vaccine (MMR) in a mumps outbreak setting.
The recommended childhood and adolescent immunization schedules for 2018 have been approved by the American Academy of Pediatrics, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC), the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists.
Results found that among portal users, 14% (702/5,000) of portal and IVR call recipients received EHR-documented influenza vaccines.
Influenza related deaths have been show to increase significantly in the home counties of Super Bowl participating teams compared to non-competing counties.
Efficient replication was reported for West Nile virus and Powassan virus in second-trimester human maternal (decidua) and fetal (chorionic villi and fetal membrane) explants, while less efficient replication was seen for CHIKV and MAYV.
The researchers found that the rate of sustained virologic response at 12 weeks was 99.1% among genotype 1-infected patients in the eight-week group and 99.7% in the 12-week group.
In a self-controlled case series, patients were observed to have increased incidence of hospital admissions for acute myocardial infarction (MI) within seven-days of respiratory virus detection.
The researchers identified a non-statistically significant increase in total birth defects potentially related to Zika virus infection in areas with local transmission, from 2.8 to 3.0 cases per 1,000 live births in the first and second halves of 2016, respectively (P=0.10).
The researchers found that HIV+ and HEU children had lower cognitive and motor scores than their HUU peers within the meta-analysis.
Sofosbuvir protected and rescued neural cells infected by the Zika virus in cell cultures and mouse models, and blocked transmission of the virus to mouse fetuses.
Shorter duration of glecaprevir-pibrentasvir effective against hepatitis C virus: The ENDURANCE trials
Both 8 and 12-week regimens of glecaprevir-pibrentasvir were highly efficacious in producing sustained virologic response in patients infected with hepatitis C virus (HCV) genotypes 1 and 3, and the 8-week treatment duration was noninferior to 12-week duration.
The incidence ratio was 6.05 for admission for acute myocardial infarction during the risk interval versus the control interval. After day 7 there was no increased incidence.
The privacy breach occurred in July 2017, when letters outlining that beneficiaries could now pick up their medications in person were sent in envelopes with large address windows which made private health information visible.
Juluca was approved as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.